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Abstract
Background: HER2 is an oncogene, expression of which leads to poor prognosis in 30% of breast cancer patients.
Although trastuzumab is apparently an effective therapy against HER2-positive tumors, its systemic toxicity and
resistance in the majority of patients restricts its applicability. In this study we evaluated the effects of phenethyl
isothiocyanate (PEITC) in HER2-positive breast cancer cells.
Methods: MDA-MB-231 and MCF-7 breast cancer cells stably transfected with HER2 (high HER2 (HH)) were used in this
study. The effect of PEITC was evaluated using cytotoxicity and apoptosis assay in these syngeneic cells. Western
blotting was used to delineate HER2 signaling. SCID/NOD mice were implanted with MDA-MB-231 (HH) xenografts.
Results: Our results show that treatment of MDA-MB-231 and MCF-7 cells with varying concentrations of PEITC for
24 h extensively reduced the survival of the cells with a 50% inhibitory concentration (IC50) of 8 μM in MDA-MB-
231 and 14 μM in MCF-7 cells. PEITC treatment substantially decreased the expression of HER2, epidermal growth
factor receptor (EGFR) and phosphorylation of signal transducer and activator of transcription 3 (STAT3) at Tyr-705.
The expression of BCL-2-associated × (BAX) and BIM proteins were increased, whereas the levels of B cell
lymphoma-extra large (BCL-XL) and X-linked inhibitor of apoptosis protein (XIAP) were significantly decreased in
both the cell lines in response to PEITC treatment. Substantial cleavage of caspase 3 and poly-ADP ribose
polymerase (PARP) were associated with PEITC-mediated apoptosis in MDA-MB-231 and MCF-7 cells. Notably,
transient silencing of HER2 decreased and overexpressing HER2 increased the effects of PEITC. Furthermore,
reactive oxygen species (ROS) generation, mitochondrial depolarization and apoptosis by PEITC treatment were
much higher in breast cancer cells expressing higher levels of HER2 (HH) as compared to parent cell lines. The IC50
of PEITC following 24 h of treatment was reduced remarkably to 5 μM in MDA-MB-231 (HH) and 4 μM in MCF-7
(HH) cells, stably overexpressing HER2. Oral administration of 12 μM PEITC significantly suppressed the growth of
breast tumor xenografts in SCID/NOD mice. In agreement with our in vitro results, tumors from PEITC-treated mice
demonstrated reduced HER2, EGFR and STAT3 expression and increased apoptosis as revealed by cleavage of
caspase 3 and PARP. In addition our results show that PEITC can enhance the efficacy of doxorubicin.
Conclusions: Our results show a unique specificity of PEITC in inducing apoptosis in HER2-expressing tumor cells
in vitro and in vivo and enhancing the effects of doxorubicin. This unique specificity of PEITC offers promise to a
subset of breast cancer patients overexpressing HER2.
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Background
The HER2/neu protein belongs to the family of epider-
mal growth factor receptors (EGFRs) and is known to be
amplified in several neoplasms such as breast, salivary
gland, stomach, kidney and lung. It is overexpressed in
about 30% of breast cancer patients [1-6]. The cytoplas-
mic domain of this intact tyrosine kinase receptor has
been implied to generate normal mitogenic as well as
transforming signals [7], indicating its direct role in cell
proliferation [8]. HER2 expression has been correlated
with poor prognosis in cancer patients by mechanisms
such as impaired DNA repair [9], angiogenesis [10] and
metastasis [11]. The oncogenic property of HER2 can be
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well enunciated, but its role in chemotherapy is not
clearly elucidated because of its obscured molecular
mechanisms. Though there are effective approaches for
targeting HER2 such as trastuzumab (herceptin), which is
a specific antibody for HER2, it is associated with toxicity
and/or resistance. This implies a need for the search of
better therapeutic agents that can target HER2-positive
cancer cells.
Doxorubicin (Adriamycin) is used to treat patients in the
early stages of breast cancer. The normal dosage of doxor-
ubicin usually ranges 40 to 60 mg/m2. It is well established
that a significant percentage of patients on doxorubicin
therapy face a risk of cardiotoxocity at these doses [12]. A
lifetime cumulative dose of about 500 mg/m2 has been
associated with chronic cardiotoxicity [13]. To avoid the
drawbacks of doxorubicin, it is important to find novel
therapies that can reduce its dose without compromising
its therapeutic effects. It has been shown that doxorubicin
can downregulate EGFR but not HER2 [14]. The approach
of combination therapies can help to enhance its efficacy
in HER2-positive patients.
Interestingly in two clinical studies, it was observed
that HER2-positive tumors responded better to the che-
motherapy regimen than HER2-negative tumors [15,16].
Another study illustrated that cleavage of HER2 mediated
apoptosis in cancer cells by inducing intrinsic apoptosis
pathway [17]. These studies indicated that the role of
HER2 may be reciprocating between antiapoptotic and
proapoptotic, but the conditions and agents that modu-
lated this balance need to be identified. These studies
also raised a question on the role of HER2 in cancer and
provide rationale to study its possible dual role.
Various recent epidemiological studies have indicated
that consumption of cruciferous vegetables such as gar-
den cress, broccoli and so on, reduces the risk of breast
cancer [18,19]. The glucosinolate-derived phenethyl iso-
thiocyanates (PEITC) present in these vegetables has pro-
mising antitumorigenic effects, as mentioned by various
studies [19-23]. Clinical studies on PEITC for lung cancer
are currently underway [24]. These facts reinforce the
importance and necessity of more preclinical studies
required on this compound to expand and discover its
true potential in breast cancer.
Our current studies establish the anticancer effects of
PEITC in HER2-positive tumor cells. Our results show
that the growth suppressive effects of PEITC in breast
cancer cells were mediated by HER2 depletion in both in
vitro and in vivo models and that HER2-expressing cells
were more sensitive to PEITC-induced apoptosis. In
addition, our study shows that in combination, PEITC
can significantly enhance the apoptosis-inducing effects
of doxorubicin. Our study provides a direction towards




Human breast carcinoma cell lines MCF-7 and MDA-MB-
231 were obtained from American Type Culture Collec-
tion (ATCC; http://www.atcc.org) and were maintained in
minimal essential medium (MEM) supplemented with
10% fetal bovine serum (FBS), 5% penicillin/streptomycin/
neomycin (PSN) and 0.01 mg/ml insulin and Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10%
FBS and 5% PSN, respectively, unless otherwise stated.
The HER2 overexpressing cells MDA-MB-231 (high
HER2 (HH)) cells and their vector controls were kindly
provided by Dr Patricia S Steeg (National Institutes of
Health, Bethesda, MD, USA) and Dr Quentin Smith
(Texas Tech University Health Sciences Center, Amarillo,
TX, USA) and were maintained in DMEM supplemented
with 10% FBS, 5% penicillin, streptomycin, neomycin solu-
tion and 300 μg/ml zeocin. HER2 was transfected in brain
seeking subset of MDA-MB-231 cells. No significant dif-
ference was observed at molecular level in these cells and
parental MDA-MB-231 cells. The MCF-7 overexpressing
HER2 cells were kindly provided by Dr Huang Fei (Bris-
tol-Myers Squibb Co., Princeton, NJ, USA) and were cul-
tured in DMEM supplemented with 10% FBS and 5%
PSN. The ATCC uses DNA fingerprinting (microsatellite
analysis) for cell line authentication. All the cells used in
this study were within 20 passages after receipt or
resuscitation.
Cytotoxicity studies
Cells were plated at a density of 2,000 to 5,000 cells/well
in 96-well plates, allowed to attach overnight and treated
with different concentrations of PEITC (molecular weight
163.2; purity > 99%; Sigma Aldrich, St. Louis, MO, USA)
for various time intervals. The cells were fixed with ice
cold 10% trichloroacetic acid, washed and stained with
sulforhodamine B dye. The optical density was measured
in Tris base solution using a plate reader after washing
the dye with 1% acetic acid solution as described by us
previously [25].
Annexin V-fluorescein isothiocyanate (FITC) apoptosis
assay
The apoptosis assay was performed using a kit (BD Bios-
ciences, San Jose, CA, USA) according to manufacturer’s
instructions. Approximately 0.3 × 106 cells were plated
into six-well plates and left overnight for attachment.
After treatment for 24 h with 0 to 15 μM PEITC, cells
were harvested by trypsinization and suspended in phos-
phate-buffered saline (PBS) to a cell density of 1 × 106/ml.
A total of 100 μl of binding buffer, 5.0 μl of Annexin
V-FITC and 5 μl of propidium iodide were added to the
suspension and incubated for additional 20 minutes at
room temperature in the dark. Total sample volume was
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made up to 500 μl with binding buffer. Samples were incu-
bated on ice in the dark and analyzed by flow cytometer
after vortexing (Accuri C6, Ann Arbor, MI, USA).
Enzyme-linked immunosorbent assay (ELISA) apoptosis
assay
Histone associated DNA fragmentation during apoptosis
was analyzed using an ELISA kit (Roche Applied
Science, Indianapolis, IN, USA). Approximately 1.0 ×
104 cells were plated in each well in a 96 well plate and
left overnight for attachment. After being treated with
different concentrations of PEITC for 24 h, cells were
processed according to the manufacturer’s instructions
and as described by us previously [26].
Hydrogen peroxide determination
Cells were plated in a six-well plate at a density of 0.3 ×
106 cells per well and were allowed to attach overnight.
After 24 h of treatment with PEITC, cells were har-
vested and lysed as described under western blotting
analysis to collect and estimate the protein. The protein
was transferred to 96 well plates at a concentration of
5 μg per well. The hydrogen peroxide (H2O2) content
was determined using the Quantichrom (Bioassay Sys-
tems, Hayward, CA, USA) peroxide assay kit as per the
manufacturer’s instructions and described by us [27].
Mitochondrial membrane potential
Cells were plated at a density of 0.3 × 106 cells/well in a
six-well plate, allowed to attach overnight and treated
with 10 μM PEITC for 24 h. Prior to collection, cells
were incubated with 100 nM tetramethylrhodamine
(TMRM) (Life Technologies, Grand Island, NY, USA)
for 20 minutes. Cells were washed with PBS, resus-
pended in fluorescence-activated cell sorting (FACS)
running buffer and analyzed by flow cytometry (Accuri
C6) as described by us [27].
Western blot analysis
The cells were treated with varying concentrations of
PEITC (5, 10 and 15 μM) for 24 h. In a time-dependent
study, cells were treated with 10 μM PEITC for 0, 1, 2,
4, 8, 12, 16, 24 and 48 h. In another experiment, MDA-
MB-231 cells were treated with 10 mM Tiron for 1 h
prior to treatment with 10 μM PEITC for 24 h. Whole
cell lysates were prepared using 4% (w/v) CHAPS buffer
(6 M urea, 2 M thiourea, 10 mM Tris pH 7.4) while
tumor lysates were prepared by homogenizing the
tumors in PBS. Control and treated protein was sub-
jected to sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE), and the segregated protein was
transferred on a polyvinylidene fluoride (PVDF) mem-
brane. The membrane was developed as described by us
previously using primary antibodies specific to human
HER2 (Abcam, Cambridge, MA, USA; 1:700), EGFR
(Cell Signaling, Danvers, MA, USA; 1:1000), phosphory-
lated signal transducer and activator of transcription 3
(p-STAT3) (Y705) (Cell Signaling, Danvers, MA, USA;
1:1000), STAT3 (Cell Signaling, Danvers, MA, USA;
1:1000), BIM (Cell Signaling, Danvers, MA, USA;
1:2000), BCL-2-associated × (BAX) (Cell Signaling, Dan-
vers, MA, USA; 1:2000), B-cell lymphoma-extra large
(BCL-XL) (Cell Signaling, Danvers, MA, USA; 1:1000),
X-linked inhibitor of apoptosis protein (XIAP) (Cell Sig-
naling, Danvers, MA, USA; 1:1000), cleaved caspase 3
(Cell Signaling, Danvers, MA, USA; 1:1000), cleaved
poly-ADP ribose polymerase (PARP) (Cell Signaling,
Danvers, MA, USA; 1:1000) and actin (Sigma Aldrich,
St. Loius, MO, USA; 1:10,000) [28,29].
Mitochondria-free cytosolic fractionation
The cell fractionation was performed using the mito-
chondrial extraction kit (Pierce, Rockford, IL, USA) as
per the manufacturer’s instructions. The cells were pla-
ted at density of 5 × 106 cells per 150 mm petri dish,
left at incubation for attachment overnight and then
treated with 10 μM PEITC for 24 h. Cells were har-
vested using trypsin after treatment and processed as
per manufacturer’s instructions.
HER2 silencing using HER2 small interfering (si)RNA
Approximately 0.3 × 106 cells were plated in a six-well
plate and left overnight for attachment. The next day
cells were transfected with HER2 siRNA or scrambled
siRNA (Cell Signaling, Danvers, MA, USA) as per man-
ufacturer’s instructions using siPORT transfection
reagent. After 2 days of transfection, cells were treated
with 10 μM PEITC for 24 h, and the cell lysate was
used for western blotting.
HER2 overexpression by transient transfection
HER2 plasmid with pcDNA3 vector backbone was
obtained from Addgene. Approximately 0.3 × 106 cells
per well were plated in six-well plates and left overnight
for attachment. The next day cells were transfected with
5 μg HER2 plasmid using Xfect Transfection reagent
(Clontech, Mountainview, CA, USA) as per manufac-
turer’s instructions. After 2 days of transfection, cells
were treated with 10 μM PEITC. After 24 h of treat-
ment, cell lysate was analyzed by western blotting.
Immunofluorescence
Sections of approximately 20 micron were obtained
from snap frozen tumor tissues for tumor analysis. The
sections were gently placed on positively charged slides,
fixed using 4% paraformaldehyde and blocked with 5%
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goat serum for 60 minutes as described by us previously
[30]. For immunostaining cells were plated in a six-well
plate on a coverslip at a density of 0.1 × 106 cells/well,
allowed to attach overnight and treated with 10 μM
PEITC for 24 h. Cells were rinsed twice with PBS for
5 minutes each, fixed with an ice cold mixture of acet-
one and methanol (1:1), rinsed with PBS and blocked
with 5% goat serum for 60 minutes. Eventually, cells
and tumor sections were probed with antibodies specific
to HER2, p-STAT3 (Y705) and cleaved caspase 3 over-
night at 4°C, followed by incubation with Alexa Fluor
488 (anti-mouse) and Alexa Fluor 594 (anti-rabbit) sec-
ondary antibodies for 1 h by gentle rocking at room
temperature. After washing the cells with PBS three
times, the nucleus was counterstained with DRAQ
5 (Axxora LLC, San Diego, CA, USA). Cells and tumor
sections were photographed under microscope (Olym-
pus Inc.) after coverslips were mounted on the slides.
Tumor therapy model
Female SCID/NOD mice (4 to 6 weeks old) were
obtained from Charles River (Wilmington, MA, USA)
and maintained under specific pathogen-free conditions.
The use of SCID/NOD mice and their treatment was
approved by the Institutional Animal Care and Use
Committee (IACUC), Texas Tech University Health
Sciences Center, and the experiments were conducted in
strict compliance with the regulations. Mice were given
antioxidant-free AIN-76A special diet (TestDiet, Rich-
mond, IN, USA) 1 week before starting the experiment.
Exponentially growing MDA-MB-231 (HH) cells were
harvested, washed twice with PBS and resuspended in
1:1 PBS/matrigel at a density of 50 × 106 cells per ml. A
suspension of 0.1 ml containing 5 × 106 cells was
injected in the right flank subcutaneously in the recipi-
ent mouse. Tumor volumes were measured three times
a week (Monday, Wednesday and Friday), and animal
weights were taken twice a week (Monday and Friday)
as described by us previously [26,30]. The tumor
volumes were calculated from tumor lengths and widths
using the formula (length × (width)2/2) [31]. When the
tumors reached a size of about 150 mm3, mice were
randomly segregated into two groups with ten mice in
each group. Test group of mice received 12 μmol
PEITC (81 mg/kg) in PBS by oral gavage every day until
day 35, whereas control mice received vehicle alone. No
obvious signs of toxicity or discomfort were observed in
the mice orally gavaged over the time. Mice were killed
on day 35 by CO2 overdose, and death was confirmed
by cervical dislocation in accordance with IACUC guide-
lines. The tumors were removed aseptically from each
mouse and were snap frozen in liquid-nitrogen after tak-
ing the tumor weights for western blot analysis and
immunofluorescence analysis.
Combination of doxorubicin and PEITC
The effect of PEITC in combination with conventional
chemotherapy agent doxorubicin (purity > 98%, Sigma
Aldrich, St. Loius, MO, USA) was evaluated in MDA-
MB-231 and MDA-MB-231 (HH) cells. In brief, cells
were treated with 4 μM PEITC and 3 μM doxorubicin
for 24 h and analyzed by sulforhodamine B cell survival
assay and western blotting as described above.
Statistical analysis
The statistical calculations and analysis were performed
using Prism 5.0 (GraphPad Software Inc., San Diego,
CA, USA). Results represent means ± SD or SEM of at
least three independent experiments. Data was analyzed
by Student’s t test. Differences were considered statisti-
cally significant at P < 0.05.
Results
PEITC inhibits the proliferation of breast cancer cells
We first determined the optimum concentration at
which PEITC could inhibit the proliferation of breast
cancer cells. Treatment of MDA-MB-231 cells with
increasing concentrations of PEITC significantly reduced
the survival of these cells in a concentration and time-
dependent manner with a 50% inhibitory concentration
(IC50) of 8 μM and 4 μM following 24 and 72 h of treat-
ment respectively (Figure 1A). However, the effect of
PEITC in MCF-7 cells was relatively less under similar
conditions with an IC50 of 14 μM and 5 μM after
24 and 72 h of treatment respectively (Figure 1B), indi-
cating that MCF-7 cells were relatively resistant to the
cytotoxic effects of PEITC as compared to MDA-MB-
231 cells.
PEITC causes induction of apoptosis
To gain further insight into the mechanism of the
growth inhibitory effects of PEITC, MDA-MB-231 and
MCF-7 cells were treated with different concentrations
of PEITC for 24 h and analyzed for apoptosis using
Annexin V assay. As shown in Figure 1C, PEITC treat-
ment induced about fourfold apoptosis in MDA-MB-
231 cells at concentration as low as 5 μM. However,
5 μM PEITC induced twofold apoptosis in MCF-7 cells
(Figure 1D). To confirm these observations, apoptosis
was also evaluated using a cell death detection ELISA
kit. Consistent with our Annexin V apoptosis data,
PEITC induced apoptosis in both MDA-MB-231 and
MCF-7 cells in a concentration-dependent manner
(Additional file 1, Figure S1A, B).
PEITC treatment depletes the HER2 level and induces the
mitochondrial pathway of apoptosis
To determine the mechanism of cell death induced by
PEITC treatment, cell lysates were analyzed by western
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Figure 1 Phenethyl isothiocyanate (PEITC) induces cell death in breast cancer cells. (A) MDA-MB-231, (B) MCF-7 cells were treated with
increasing concentrations of PEITC for 24, 48 and 72 h. Cell survival was measured with sulforhodamine B assay to estimate the IC50 values. The
experiments were repeated at least three times with eight replicates in each experiment. (C) MDA-MB-231 and (D) MCF-7 cells were treated with
or without PEITC (2.5, 5, 10, 15 μM) for 24 h. Cells were then collected and labeled with annexin V/fluorescein isothiocyanate (FITC). Cells that
were positive for annexin or propidium iodide or both were measured using flow cytometry. Representative images are shown. Each experiment
was repeated more than three times independently. *Statistically different when compared with control (P < 0.05).
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blotting. Consistent with previous observations MDA-
MB-231 and MCF-7 cells showed constitutive levels of
HER2 (Figure 2A, B) [32-34]. Our results show that treat-
ment of MDA-MB-231 cells with PEITC after 24 h of
treatment significantly reduced HER2 and EGFR expres-
sion in a concentration-dependent manner (Figure 2A).
PEITC treatment also substantially reduced the expression
and phosphorylation of STAT3 at Tyr-705. STAT3 plays a
critical role in the expression of cell proliferative pathways
and is known to be activated in breast tumors [35].
Furthermore, treatment of cells with PEITC notably
increased the levels of proapoptotic proteins such as BIM
and BAX and concomitantly decreased the expression
of antiapoptotic proteins such as XIAP and BCL-XL
(Figure 2A). We also observed an increase in the cleaved
fragments of caspase 3 and PARP in PEITC-treated MDA-
MB-231 cells, indicating apoptosis (Figure 2A). Similar
observations were made in the other breast cancer cell line
MCF-7 (Figure 2B). In a time-dependent experiment,
HER2 downregulation started around 8 h of PEITC treat-
ment in MDA-MB-231 cells (Figure 3A). Interestingly,
cleavage of proapoptotic proteins BIM and caspase 3
started appearing around 8 h of PEITC treatment, suggest-
ing that HER2 downregulation was associated with the
induction of apoptosis (Figure 3A). Since PEITC-modu-
lated BAX and BH3 interacting-domain death agonist
(BID) expression indicated the involvement of mitochon-
dria, induction of apoptosis by mitochondrial pathway was
further confirmed by the release of cytochrome c into cyto-
sol (Figure 3B). As shown in Figure 3B, 10 μM PEITC
treatment for 24 h substantially increased cytosolic cyto-
chrome c level and decreased the expression of BCL-XL.
The downregulation of HER2 was also confirmed by the
immunofluorescence. The staining of HER2 was markedly
less in PEITC treated MDA-MB-231 cells as compared to
control cells (Figure 3C).
HER2 silencing blocks PEITC-induced apoptosis
To evaluate the role of HER2 in PEITC-induced apoptosis,
HER2 was silenced in MDA-MB-231 cells using HER2
siRNA. We were able to silence about 78% of HER2
expression by HER2 siRNA in MDA-MB-231 cells (Figure
4A). The silencing of HER2 reduced the cleavage of cas-
pase 3 and PARP by PEITC treatment as compared to
control MDA-MB-231 cells transfected with scrambled
siRNA (Figure 4A). These results were also confirmed by
the ELISA cell death detection assay (Additional file 2, Fig-
ure S2A). Silencing of HER2 reduced cell death induced by
PEITC indicating the critical role of HER2 in PEITC-
induced apoptosis.
Overexpression of HER2 enhanced PEITC-induced apoptosis
Next, we were interested to see if HER2 overexpression
could enhance PEITC-mediated apoptosis. We transfected
MCF-7 cells with HER2-expressing plasmid and treated
the cells with PEITC. Using transient transfection, we
were able to achieve approximately 2.5-fold overexpression
of HER2 in these cells. MCF-7 cells were chosen for HER2
transfection, because MCF-7 cells were relatively resistant
to the cytotoxic effects of PEITC (Figure 1A, B). As shown
in Figure 4B, overexpression of HER2 led to more PARP
cleavage by PEITC treatment. Furthermore, significantly
more apoptosis was observed by PEITC treatment in
MCF-7 cells overexpressing HER2, as measured by ELISA
cell death detection assay, confirming our observation
made by western blotting (Additional file 2, Figure S2B).
Effect of PEITC treatment in cells stably overexpressing
HER2
Because we observed that transiently overexpressing HER2
enhanced the cytotoxic effects of PEITC, we next sought
to determine the effect of PEITC in MDA-MB-231 and
MCF-7 cells stably overexpressing HER2 (HH). First of all,
we compared the effect of PEITC in both the cell lines sta-
bly overexpressing HER2 with that of the cells with consti-
tutive levels. Humongous overexpression of HER2 was
observed in stably transfected MDA-MB-231 and MCF-7
cells, respectively, as compared to the parent cell lines or
vector transfected control cells (Figures 5A and 6A). In
addition increased phosphorylation of STAT3 was
observed in both MDA-MB-231 and MCF-7 cells expres-
sing high HER2 levels, indicating the regulation of STAT3
by HER2 (Figures 5A and 6A). Nevertheless, the expres-
sion of HER2 was drastically reduced by PEITC treatment
in both the cells overexpressing HER2 (Figures 5A and
6A). As shown in Figure 5A, MDA-MB-231 cells overex-
pressing HER2 (MDA-MB-231 (HH)) showed enhanced
PARP cleavage as compared to the parent or vector trans-
fected control cells in response to PEITC treatment. These
observations were confirmed by ELISA cell death detec-
tion assay, where MDA-MB-231 (HH) cells showed more
apoptosis relative to the parent cell line or vector trans-
fected control cells at all the concentrations of PEITC
(Figure 5B and Additional file 3, Figure S3A). Similar
observations were made in MCF-7 cells overexpressing
HER2, but the effect of PEITC was more in MCF-7 (HH)
cells as compared to MDA-MB-231 (HH) cells (Figure 6A
and Additional file 3, Figure S3B).
To determine the effect of PEITC on HER2 responsive
and proapoptotic proteins, HER2-overexpressing cells
were treated with varying concentrations of PEITC for 24
h and evaluated by western blot. Consistent with MDA-
MB-231 and MCF-7 parent cell lines data, PEITC treat-
ment substantially reduced the expression of HER2,
EGFR, STAT3 and phosphorylation of STAT3 in MDA-
MB-231 (HH) cells overexpressing HER2 (Figure 5C).
Proapoptotic proteins BIM, BAX and BID were highly
activated by PEITC treatment, whereas antiapoptotic
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Figure 2 Phenethyl isothiocyanate (PEITC) downregulates HER2 signaling in breast cancer cells. (A) MDA-MB-231 and (B) MCF-7 cells
were treated with varying concentrations of PEITC for 24 h. Representative blots showing the concentration dependent effect of PEITC on HER2,
epidermal growth factor receptor (EGFR), phosphorylated signal transducer and activator of transcription 3 (p-STAT3) (Y705), BIM, BCL-2-
associated × (BAX), B-cell lymphoma-extra large (BCL-XL), X-linked inhibitor of apoptosis protein (XIAP), BH3 interacting-domain death agonist
(BID), cleaved caspase 3 and cleaved poly-ADP ribose polymerase (PARP). Actin was used as internal loading control. Each experiment was
repeated three times independently.
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BCL-XL and XIAP were significantly downregulated (Fig-
ure 5C). Substantial cleavage of caspase 3 and PARP was
also observed in MDA-MB-231 (HH) cells in response to
PEITC treatment (Figure 5C). Notably, cleavage of cas-
pase-3 and/or PARP was substantially more in MDA-
MB-231 (HH) cells by PEITC treatment as compared to
parental cells. Similar observations were made in MCF-7
(HH) cells overexpressing HER2 (Figure 6B). Next, we
wanted to see whether the overexpression of HER2
would increase the cytotoxic potential of PEITC. There-
fore a cell survival assay was performed in MDA-MB-231
(HH) and MCF-7 (HH) cells after treatment with PEITC.
As shown in Figure 5D, PEITC treatment significantly
reduced the survival of MDA-MB-231 (HH) cells with an
IC50 of 5 μM and 2 μM after 24 h and 72 h of treatment
respectively. When compared with parent MDA-MB-231
cells, the IC50 of PEITC was about 38% to 50% less in
MDA-MB-231 (HH) cells. Similarly, PEITC treatment
decreased the survival of MCF-7 (HH) cells with an IC50
of 4 μM and 3 μM respectively after 24 h and 72 h treat-
ment (Figure 6C). The IC50 of PEITC in MCF-7 (HH)






















Figure 3 HER2 downregulation by phenethyl isothiocyanate (PEITC) leads to mitochondrial death pathway. (A) Time-dependent effect of
10 μM PEITC in MDA-MB-231 cells. (B) PEITC treatment mediated cytochrome c release in the cytosol. Mitochondria-free cytosol was used to
detect cytochrome c in control and treated cells. Actin was used as loading control. (C) Representative images of HER2 immunofluorescence in
MDA-MB-231 in control and PEITC treated cells. Each experiment was repeated three times independently.
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MCF-7 cells by PEITC treatment. Taken together, these
results clearly indicated that HER2 makes breast cancer
cells more sensitive to the growth suppressive effects of
PEITC.
PEITC decreases mitochondrial membrane potential
Since we observed the involvement of mitochondrial
proteins in PEITC-induced apoptosis, we next deter-
mined mitochondrial membrane potential using TMRM
as a specific probe. PEITC treatment caused about 15%
decrease in the membrane potential in MDA-MB-231
cells as compared to 54% decrease in MDA-MB-231
(HH) (Figure 7A). Once again our results indicated that
HER2 sensitizes MDA-MB-231 cells to the mitotoxic
effects of PEITC.
Reactive oxygen species (ROS) induction by PEITC
treatment
Depolarization of mitochondria leading to cell death is
usually due to excessive generation of ROS in the cells.
We therefore measured hydrogen peroxide concentra-
tion in the cells using a commercial kit. As shown in
Figure 7B, hydrogen peroxide level was much higher in
MDA-MB-231 (HH) cells as compared to MDA-MB-
231 cells in response to PEITC treatment (Figure 7B).
Similar observations were made in MCF-7 (HH) cells
(Figure 7C). These results once again indicate that
HER2 increased the ability of breast cancer cells to gen-
erate hydrogen peroxide in response to PEITC treat-
ment leading to cell death. The next step was to
determine whether ROS (hydrogen peroxide) were
involved in the downregulation of HER2 and apoptosis
by PEITC treatment. In order to prove this association,
MDA-MB-231 cells were pretreated with 10 mM Tiron
(a general antioxidant) for 1 h to block ROS followed by
treatment with 10 μM PEITC for 24 h. As shown in Fig-
ure 7D, Tiron treatment considerably blocked the down-
regulation of HER2 by PEITC treatment. Tiron also
substantially decreased the apoptosis induced by PEITC
treatment as shown by reduced cleavage of caspase-3
(Figure 7D).
Tumor therapy model
Since we consistently observed that HER2-overexpressing
cells were more sensitive to PEITC, we next evaluated
the efficacy of PEITC in vivo. About 5 × 106 MDA-MB-
231 (HH) cells were implanted in SCID/NOD mice subcu-
taneously. After each mouse had a tumor of about
150 mm3, 12 μmol PEITC treatment by oral gavage started.
Our results show that PEITC treatment significantly sup-
pressed the growth of breast tumors (Figure 8A). At
day 35 of PEITC treatment, tumor volume in the treated
group was reduced by 45% as compared with control
group (552.8 ± 90.3 mm3 vs 295.4 ± 44.2 mm3; n = 10)
(Figure 8A). Similarly, the average weight of the tumors
dissected from PEITC-treated mice was approximately 43%
less than the weight of the tumors from control mice
(Figure 8B). The weight of the mice did not change at all

























































































































Figure 4 Change in HER2 expression modulates the effect of
(PEITC). (A) Effect of PEITC in HER2-silenced MDA-MB-231 cells. At
48 h after transfection of cells with HER2 siRNA, cells were treated
with or without 10 μM PEITC for 24 h. Whole cell lysate was
evaluated for phosphorylation of signal transducer and activator of
transcription 3 (STAT3), cleavage of caspase 3 and poly-ADP ribose
polymerase (PARP). (B) Effect of transient HER2 overexpression on
apoptosis induction in MCF-7 by PEITC treatment. After 48 h of
HER2 transfection, cells were treated with or without 10 μM PEITC
for 24 h. The means of two independent experiments performed in
duplicate are shown.
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Figure 5 Effect of phenethyl isothiocyanate (PEITC) on MDA-MB-231 cells expressing high HER2 (HH). (A) Comparative effect of PEITC
treatment on MDA-MB-231 cells with stable overexpression of HER2 relative to parent cells and vector control cells. Cells were treated for 24 h
with 10 μM PEITC, and whole lysate was analyzed by western blotting for phosphorylated signal transducer and activator of transcription 3 (p-
STAT3) (Y705) and cleavage of poly-ADP ribose polymerase (PARP). (B) MDA-MB-231, vector control cells and high HER2 cells were treated with
10 μM of PEITC for 24 h and apoptosis was estimated using ELISA cell death assay by measuring histone associated DNA fragments. (C) MDA-
MB-231 (HH) cells were treated with different concentrations of PEITC for 24 h, and the whole cell lysates were analyzed by western blotting. (D)
MDA-MB-231 (HH) cells were treated with PEITC for 24, 48 and 72 h with increasing concentrations of PEITC and cell survival was measured by
sulforhodamine B assay. The figures are representative of at least three independent experiments with eight replicates. *Statistically different
compared with control (P < 0.05).
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Figure 6 Effect of phenethyl isothiocyanate (PEITC) on MCF-7 (high HER2 (HH)) cells. (A) Comparative effect of PEITC treatment in MCF-7
cells with stable overexpression of HER2 relative to the parent cells. Cells were treated for 24 h with 10 μM PEITC and whole lysate was
analyzed by western blotting for phosphorylated signal transducer and activator of transcription 3 (p-STAT3) (Y705) and cleavage of poly-ADP
ribose polymerase (PARP). (B) MCF-7 (HH) cells were treated with different concentrations of PEITC for 24 h, and the whole cell lysates were
analyzed by western blotting. (C) MCF-7 (HH) cells treated with PEITC for 24, 48 and 72 h with increasing concentrations of PEITC and cell
survival was measured by sulforhodamine B assay. The figures are representative of at least three independent experiments with eight replicates.
*Statistically different compared with control (P < 0.05).
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systemic toxicity in PEITC-treated mice (Figure 8C). The
tumors of control and PEITC-treated mice were further
analyzed by western blotting and immunofluorescence.
Consistent with our in vitro results, western blot of the
tumor lysate shows that PEITC treatment substantially
downregulated HER2 expression and phosphorylation of
STAT3 (Figure 8D). We also observed a decrease in EGFR
expression in the tumors of PEITC-treated mice, but it was
not as pronounced as HER2 downregulation. It is note-
worthy that substantial upregulation of BIM and cleavage
of caspase 3 and PARP were observed in the tumors of
PEITC-treated mice as compared to control indicating
apoptosis (Figure 8D). However, expression of antiapopto-
tic proteins such as BCL-XL and XIAP were reduced
(Figure 8D). These observations were confirmed by the
immunofluorescence studies in the tumor sections of con-
trol and PEITC-treated mice. The staining for HER2 and
phosphorylated STAT3 were reduced; whereas cleavage of
caspase 3 was increased in the tumor sections from
PEITC-treated mice (Additional file 4, Figure S4). Taken
together, our results show that tumor growth suppression
by PEITC treatment was associated with HER2 downregu-
lation and increased apoptosis, in agreement with our
in vitro results.
PEITC enhances the effects of doxorubicin
Next, we wanted to determine whether the effects of dox-
orubicin could be enhanced at low concentrations, since
the regular doses currently being used by the patients are
associated with severe cardiotoxicity. Furthermore, HER2
overexpression is known to reduce the efficacy of doxor-
ubicin. In order to do this, cells were treated with sub
toxic concentrations of 4 μM PEITC and 3 μM doxorubi-
cin for 24 h. It is important to mention that the IC50
values of PEITC and doxorubicin were 8 μM and 6 μM
in MDA-MB-231 and 5 μM and 10 μM in MDA-MB-231
(HH) cells after 24 h of treatment. Our results show that
individual treatment of 4 μM PEITC or 3 μM doxorubi-
cin reduced the cell survival by 20%. However, combina-
tion of PEITC and doxorubicin treatment for 24 h
reduced 50% cell survival (Figure 9A). Doxorubicin
(3 μM) treatment suppressed HER2 expression modestly,
whereas PEITC (4 μM) decreased the expression signifi-
cantly (Figure 9B). Nonetheless, the combination of
PEITC with doxorubicin substantially decreased the
expression of HER2 and the phosphorylation of STAT3
in MDA-MB-231 cells (Figure 9B). Consistently, combi-
nation treatment showed increased cleavage of caspase 3
and PARP as compared to individual treatment indicat-
ing apoptosis (Figure 9B). Similarly in MDA-MB-231
(HH) cells, individual treatment of 4 μM PEITC or 3 μM
doxorubicin reduced the survival of cells by about 30%,
whereas combination treatment reduced 60% survival
(Figure 9C). Modest suppression of HER2 was observed
Figure 7 (PEITC) causes ROS generation and mitochondrial
depolarization. (A) MDA-MB-231 and MDA-MB-231 (high HER2
(HH)) cells were treated with PEITC for 24 h and then were labeled
with tetramethylrhodamine and analyzed by flow cytometer (n = 3).
Hydrogen peroxide content was measured in control or 10 μM
PEITC-treated (B) MDA-MB-231 and MDA-MB-231 (HH) cells and (C)
MCF-7 and MCF-7 (HH) cells. (D) MDA-MB-231 cells were treated
with 10 mM Tiron followed by treatment with 10 μM PEITC for 24
h. The cell lysate was analyzed for HER2 expression. Statistically
different when compared with control (P < 0.05).
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Figure 8 Phenethyl isothiocyanate (PEITC) suppresses the growth of MDA-MB-231 (high HER2 (HH)) tumors by inhibiting HER2 in
SCID/NOD mice. About 5 × 106 MDA-MB-231 (HH) cells were subcutaneously implanted into the right flanks of SCID/NOD mice. Once each
mouse had a tumor of about 150 mm3, mice started receiving 12 μmol of PEITC by oral gavage every day. Tumors were measured three times a
week, and each mouse was weighed twice a week. Effect of PEITC on (A) tumor volume, (B) tumor weight, (C) Mice weight and (D) tumor
western blots. Tumors were minced, lysed and analyzed for HER2, epidermal growth factor receptor (EGFR), phosphorylated signal transducer
and activator of transcription 3 (p-STAT3) (Y-705), STAT3 expression, BIM, B-cell lymphoma-extra large (BCL-XL), X-linked inhibitor of apoptosis
protein (XIAP), cleaved poly-ADP ribose polymerase (PARP) and cleaved caspase 3. Blots were stripped and reprobed with actin antibody to
verify equal protein loading. Each lane represents a tumor sample from different mice. The blots were quantitated, normalized with actin and
represented as bars.
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following 24 h of 4 μM PEITC treatment in MDA-MB-
231 (HH) cells. However, 3 μM doxorubicin treatment
enhanced HER2 expression in these cells. Nevertheless
24 h combination treatment with both the agents com-
pletely suppressed the overall expression of HER2 and p-
STAT3 (Y705) in these cells (Figure 9D). The enhanced
cytotoxic effect of PEITC and doxorubicin combination
was also evident by increased cleavage of caspase 3 and
PARP (Figure 9D).
Discussion
Our results indicated that PEITC treatment considerably
suppressed the viability of MCF-7 and MDA-MB-231
breast cancer cells. The reduced viability of these cells
Figure 9 Phenethyl isothiocyanate (PEITC) enhances the cytotoxic effects of doxorubicin. (A) MDA-MB-231 cells were treated with PEITC
(4 μM) and/or doxorubicin (3 μM) for 24 h and analyzed by sulforhodamine B cell survival assay. (B) MDA-MB-231 cells were treated with PEITC
(4 μM) and/or doxorubicin (3 μM) for 24 h and analyzed by western blotting for HER2 and cleavage of caspase 3 and poly-ADP ribose
polymerase (PARP). (C) MDA-MB-231 (high HER2 (HH)) cells were treated with 4 μM of PEITC and 3 μM of doxorubicin for 24 h and analyzed by
sulforhodamine B cell survival assay. (D) The cell lysates from MDA-MB-231 (HH) cells treated with 4 μM of PEITC and/or 3 μM of doxorubicin
were analyzed by western blotting for HER2, cleaved caspase 3 and PARP. Actin was used as internal loading control. Statistically different when
compared with control (P < 0.05).
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was associated with HER2/EGFR downregulation. In
addition PEITC treatment reduced the expression and
the phosphorylation of STAT3. Overexpressing HER2
using HER2 plasmid enhanced the cytotoxic potential of
PEITC in these cells. However, silencing HER2 using
siRNA blocked the apoptosis induced by PEITC treat-
ment relative to the cells with constitutive levels of
HER2. Stable overexpression of HER2 in these cells
made the cells more sensitive to the cytotoxic effects of
PEITC as indicated by reduced IC50 values. Further-
more, our results indicate that PEITC treatment induced
hydrogen peroxide production in breast cancer cells
leading to mitochondrial membrane depolarization. In
line with hydrogen peroxide production and mitochon-
drial membrane depolarization, PEITC treatment
resulted in the release of cytochrome c into the cytosol,
leading to the activation of the caspase 3 cascade. Oral
administration of PEITC significantly suppressed the
growth of breast tumors in SCID/NOD mice. Tumors
from PEITC mice demonstrated reduced expression of
HER2, EGFR, STAT3, BCL-XL and XIAP, and increased
cleavage of BIM, caspase 3 and PARP indicating apopto-
sis. To the best of our knowledge, our study for the first
time implicated the probable role of HER2 in sensitizing
breast cancer cells to PEITC-induced apoptosis in vitro
and in vivo.
HER2 is a tyrosine kinase associated with poor prog-
nosis in breast cancer [2]. Substantial evidence indicates
its direct role in tumor progression by promoting migra-
tion, invasion, antiapoptotic pathways [36] and drug
resistance [9]. Under normal conditions HER2 plays an
important role in the development of mammary glands
and lactation during parturition [37], while deregulation
of HER2 leads to the development and progression of
breast cancer [38]. Since 1989 efforts have been made to
develop therapeutics for HER2-positive breast tumors
[39,40]. Trastuzumab (herceptin), a US Food and Drug
Administration (FDA)-approved monoclonal antibody
against HER2, was apparently effective in the treatment
of HER2-positive tumors [41,42]. However, patients with
HER2-positive tumors frequently present primary or sec-
ondary resistance to this agent [43]. Also, a significant
number of patients show moderate to severe toxicity
with trastuzumab [44-46]. These detrimental side effects
of current targeted therapies raise a need for newer and
better therapeutic agents for targeting HER2. Our results
show efficacy of PEITC towards HER2-expressing breast
cancer cells. Notably, previous studies have shown that
PEITC is not toxic to normal cells [47]. Although induc-
tion of cell death has been shown by PEITC in MCF-7
cells [48], the effect of PEITC on HER2 has not been
reported so far. To ascertain the specificity of PEITC for
HER2, we tested the effect of PEITC in two prototype
and syngeneic breast cancer cell lines MDA-MB-231,
MDA-MB-231 (HH), MCF-7 and MCF-7 (HH), which
have varying levels of HER2. Interestingly we observed
increased sensitivity of the cells with higher levels of
HER2 towards PEITC. Some previous studies have
shown reduced efficiency of chemotherapeutic drugs due
to HER2 overexpression [13].
HER2 functions through homodimerization and het-
erodimerization with other EGFR family receptors to
activate further downstream effectors [12]. Some studies
indicate the role of STAT3 in EGFR signaling in various
cancers [49,50]. Our current study also indicated EGFR
inhibition in breast cancer cells by PEITC treatment.
Furthermore, inhibition of STAT3 expression and phos-
phorylation by PEITC treatment in our model indicated
the inhibition of survival pathways in breast cancer cells.
In agreement with our studies, PEITC has been shown to
suppress STAT3 activation in prostate cancer cells [51].
Silencing and overexpression of HER2 showed changes
in STAT3 phosphorylation. Though there is no estab-
lished correlation yet between HER2 and STAT3, our
results indicated that HER2 might be regulating STAT3.
Detailed studies are needed to further confirm and estab-
lish a relationship between HER2 and STAT3.
During the intrinsic mitochondrial death pathway,
cytochrome c is released from the mitochondria into the
cytosol due to a decrease in mitochondrial membrane
potential [52]. Mitochondrial membrane potential is
compromised as a result of ROS generation. Our results
show that PEITC treatment caused ROS generation and
mitochondrial depolarization, resulting in the release of
cytochrome c, hence activating caspase 3 mediated apop-
tosis in agreement with the outcome of other study [53].
Antioxidant Tiron significantly blocked the decrease in
HER2 expression and apoptosis by PEITC treatment sug-
gesting the regulation of HER2 by ROS. A recent study
suggested that certain genes that are upregulated in
HER2 tumors were activated during oxidative stress [48].
Interestingly, the extent of ROS generation and mito-
chondrial depolarization by PEITC was much higher in
HER2 overexpressing cells as compared to parent cells.
These observations suggest a link between ROS, HER2
and mitochondrial damage by PEITC in breast cancer
cells. Nonetheless, further studies are needed to correlate
HER2 and mitochondrial functions. A recent study indi-
cated the involvement of mitochondrial STAT3 in inhi-
biting ROS production via mitochondrial electron
transport chain (ETC) complex I [54]. We also observed
inhibition of mitochondrial STAT3 by PEITC treatment
in breast cancer cells (data not shown). It was not clear at
this point whether ROS generation by PEITC in our
model was through the interaction of mitochondrial
STAT3 with ETC complex I and needs further investiga-
tion. In our studies we also observed significant inhibi-
tion of XIAP by PEITC treatment. XIAP is a known
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inhibitor of apoptosis [55], and transmits survival signals
in breast cancer cells [56]. Second mitochondria-derived
activator of caspases (Smac) is a known repressor of
XIAP and is elevated during apoptosis. We did not
observe any significant change in the expression of Smac
by PEITC treatment indicating Smac-independent sup-
pression of XIAP in our model.
Oral administration of 12 μmol PEITC significantly sup-
pressed the growth of breast tumor in vivo. In a recent
study oral administration of 10 μmol/kg PEITC in rats
resulted in the peak plasma concentration of 9.2 ± 0.6 μM
PEITC [57]. Notably, the IC50 of PEITC in HER2 overex-
pressing cells in our model was less than 5 μM. These
results indicate that the therapeutic concentration of
PEITC can be achieved clinically in human patients.
Doxorubicin has been used for breast cancer treatment
for a long time, but its use has been associated with dose-
related acute and chronic toxicity in most of the patients.
Several measures have been taken to reduce its toxicity,
such as combining it with other chemotherapeutic agents
to reduce its dose without compromising its efficacy.
Interestingly, our results showed that the cytotoxic effects
of doxorubicin can be enhanced by concomitant use of
PEITC. Combination of doxorubicin with PEITC effec-
tively suppressed HER2 and STAT3 phosphorylation in
breast cancer cells, resulting in enhanced apoptosis as
compared to individual treatments respectively. These
observations have clinical relevance as our data suggests
that the effect of doxorubicin at low doses can be
increased by PEITC in HER2-expressing breast cancer
cells, which show poor response to doxorubicin therapy
in general. Detailed in vitro and in vivo studies are
required to establish this association.
Taken together, our results indicated that (i) HER2 is
a potential molecular target of PEITC in breast cancer
cells in vitro and in vivo and (ii) PEITC has a potential
to enhance the cytotoxic effects of doxorubicin. Our
study suggests a unique specificity of PEITC towards
HER2-overexpressing breast cancer cells, indicating that
PEITC could be beneficial to a subset of patient popula-
tion overexpressing HER2.
Conclusions
Our studies clearly indicate a unique specificity of
PEITC towards HER2 overexpressing breast cancer cells,
indicating that PEITC could be beneficial to a subset of
patient population overexpressing HER2, alone or in
combination with doxorubicin.
Additional material
Additional file 1: Figure S1. Phenethyl isothiocyanate (PEITC) induces
histone associated fragmentation in breast cancer cells. Apoptosis
induction was measured by enzyme-linked immunosorbent assay (ELISA)
cell death detection method in (A) MDA-MB-231 and (B) MCF-7 (n = 3).
Each experiment was repeated more than three times independently.
*Statistically different when compared with control (P < 0.05).
Additional file 2: Figure S2. Change in HER2 expression modulates the
effect of phenethyl isothiocyanate (PEITC). (A) Effect of PEITC in HER2-
silenced MDA-MB-231 cells. At 48 h after transfection of cells with HER2
siRNA, cells were treated with or without 10 μM PEITC for 24 h.
Apoptosis was measured by enzyme-linked immunosorbent assay (ELISA)
cell death detection method after silencing HER2 in MDA-MB-231 (n =
15). (B) Effect of HER2 overexpression on apoptosis induction in MCF-7
by PEITC treatment. After 48 h of HER2 transfection, cells were treated
with or without 10 μM PEITC for 24 h. The means of three independent
experiments performed in triplicate are shown. The induction of
apoptosis by ELISA cell death detection method in HER2 overexpressing
MCF-7 cells (n = 3).
Additional file 3: Figure S3. Change in HER2 expression modulates the
effect of phenethyl isothiocyanate (PEITC). (A) Comparative effect of
PEITC treatment on MDA-MB-231 cells with stable overexpression of
HER2 relative to parent cells. Cells were treated for 24 h with 10 μM
PEITC and apoptosis measured by enzyme-linked immunosorbent assay
(ELISA) cell death detection method in MDA-MB-231 parent cells and the
cells with stable overexpression of HER2, after treatment with 10 μM
PEITC for 24 h. (B) Comparative effect of PEITC treatment in MCF-7 cells
with stable overexpression of HER2 relative to the parent cells. Cells were
treated for 24 h with 10 μM PEITC and apoptosis measured by ELISA cell
death detection method in MCF-7 parent cells and the cells with stable
overexpression of HER2, after treatment with PEITC (10 μM) for 24 h. The
figures are representative of at least three independent experiments with
eight replicates. *Statistically different compared with control (P < 0.05).
Additional file 4: Figure S4. Phenethyl isothiocyanate (PEITC)
suppresses the growth of MDA-MB-231 (high HER2 (HH)) tumors by
inhibiting HER2 in SCID/NOD mice. About 5 × 106 MDA-MB-231 (HH)
cells were subcutaneously implanted into the right flanks of SCID/NOD
mice. Once each mouse had a tumor of about 150 mm3, mice started
receiving 12 μmol of PEITC by oral gavage every day. About 20 micron
sections were obtained from snap frozen tumor tissues for tumor
analysis. Immunofluorescence for HER2, phosphorylated signal transducer
and activator of transcription 3 (p-STAT3) (Y-705) and cleaved caspase 3
in tumor sections from control and PEITC treated mice. The red staining
represents the expression of HER2, p-STAT3 (Y705) and cleaved caspase
3.
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